A Multi-centre, Open Labelled, Multiple Dosing Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC 0172-2021 Administered Subcutaneously to Healthy Male Subjects and Haemophilia Subjects

Trial Profile

A Multi-centre, Open Labelled, Multiple Dosing Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC 0172-2021 Administered Subcutaneously to Healthy Male Subjects and Haemophilia Subjects

Discontinued
Phase of Trial: Phase I

Latest Information Update: 14 Feb 2017

At a glance

  • Drugs Concizumab (Primary)
  • Indications Haemophilia
  • Focus Adverse reactions
  • Acronyms Explorer 2
  • Sponsors Novo Nordisk
  • Most Recent Events

    • 29 Apr 2014 New trial record
    • 08 Jan 2014 According to ClinicalTrials.gov record, the status has changed from suspended to terminated due to the need for changes in the trial design requiring a new re-designed multiple dosing phase 1 trial.
    • 27 Sep 2012 According to ClinicalTrials.gov record, the status has changed from recruiting to suspended while awaiting protocol amendment.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top